CSIRO Publishing blank image blank image blank image blank imageBooksblank image blank image blank image blank imageJournalsblank image blank image blank image blank imageAbout Usblank image blank image blank image blank imageShopping Cartblank image blank image blank image You are here: Journals > Sexual Health   
Sexual Health
Journal Banner
  Publishing on sexual health from the widest perspective
blank image Search
blank image blank image
blank image
  Advanced Search

Journal Home
About the Journal
Editorial Structure
Online Early
Current Issue
Just Accepted
All Issues
Special Issues
Sample Issue
Call for Papers
For Authors
General Information
Submit Article
Author Instructions
Open Access
For Referees
Referee Guidelines
Review an Article
Annual Referee Index
For Advertisers
For Subscribers
Subscription Prices
Customer Service

blue arrow e-Alerts
blank image
Subscribe to our Email Alert or RSS feeds for the latest journal papers.

red arrow Connect with us
blank image
facebook twitter logo LinkedIn

red arrow Interview with Kit Fairley
blank image
Hear Kit Fairley speak about what is sexual health.


Article << Previous     |     Next >>   Contents Vol 7(3)

Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance

Michael S. Gold A D, Jim Buttery B, Peter McIntyre C

A Discipline of Paediatrics, School of Paediatrics and Reproductive Health, University of Adelaide, SA 5001, Australia.
B SAEFVIC, Department of General Medicine, Murdoch Children’s Research Institute, Royal Children’s Hospital Melbourne and Infectious Diseases Unit, Department of Paediatrics, Monash Children’s Hospital, Monash University, Melbourne, Parkville, Vic 3052, Australia.
C The National Centre for Immunisation Research, The Children’s Hospital at Westmead, Locked Bag 4001, Westmead, NSW 2145, Australia.
D Corresponding author. Email: michael.gold@adelaide.edu.au
PDF (95 KB) $25
 Export Citation


Australia was one of the first countries to licence a quadrivalent human papillomavirus (HPV) vaccine, rapidly followed by a federally funded program of universal vaccination of a broad age group of females through schools (12 to 18 years) and primary care (19 to 26 years). As of August 2009, more than 5.8 million doses of Gardasil® (quadrivalent; Merck, New Jersey, USA) have been distributed in Australia and a total of 1394 suspected adverse events following immunisation (AEFI) have been reported to the passive surveillance system. Most reports are of common and expected reactions. Case series of more uncommon and serious AEFI, both known to be potentially vaccine related (anaphylaxis, conversion disorders and lipoatrophy) and otherwise (multiple sclerosis and pancreatitis) have been published.

Keywords: adverse events following immunisations, HPV vaccine, vaccine safety.

Subscriber Login

Legal & Privacy | Contact Us | Help


© CSIRO 1996-2015